We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




High-Throughput DNA Analyzer and Dedicated Cystic Fibrosis Assays Approved for Diagnostics Use in the United States

By LabMedica International staff writers
Posted on 03 Dec 2013
The first high-throughput DNA sequencing analyzer to have been granted CE marking clearance for diagnostic use in Europe has now been approved by the [US] Food and Drugs Administration for sale in the United States.

Illumina Inc. More...
(San Diego, CA, USA) received FDA premarket (510k) clearance for the MiSeqDx high-throughput analyzer system as well as for the dedicated MiSeqDx Cystic Fibrosis (CF) 139-Variant Assay, MiSeqDx Cystic Fibrosis Clinical Sequencing Assay, and MiSeqDx Universal Kit.

The MiSeqDx Cystic Fibrosis 139-Variant Assay is a next-generation sequencing test designed for the simultaneous detection of 139 clinically relevant disease-causing mutations and variants within the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Other carrier screening methods test only for those variants most commonly found in Caucasians, potentially missing CF causative variants in a wider demographic. The Illumina assay offers the largest CF screening panel available to overcome this bias and provide comprehensive detection across diverse demographics. This results in the most complete answer the first time, reducing residual risk.

The MiSeqDx cystic fibrosis assays were developed specifically for the MiSeqDx instrument. The user needs only to prepare libraries from 250 nanograms of gDNA, load them on to the MiSeqDx for sequencing using the Illumina sequencing by synthesis (SBS) chemistry, and analyze with the user-friendly software. The automated workflow is quick and easy to perform, minimizing potential human error.

The assay kit includes everything needed for library preparation, sample multiplexing, and sequencing in a single kit. All reagents are packaged in a convenient ready-to-use format that minimizes hands-on time and insures uniformity in all tests. To accommodate a broad spectrum of testing needs, from small to large volumes, the assay is available in two kit configurations (96 or 960 tests).

The MiSeqDx Universal Kit enables clinical laboratories to develop their own diagnostic tests. The kit includes library preparation reagents, sample index primers, and sequencing consumables needed for laboratories to develop amplicon assays on the in vitro diagnostic platform.

“Illumina is proud to be the first company to obtain FDA clearance for a high-throughput DNA sequencing analyzer and next-generation sequencing-based assays,” said Greg Heath, general manager of diagnostics at Illumina. “With the FDA clearance of the MiSeqDx, Illumina is providing clinicians and clinical laboratories with the tools needed to obtain comprehensive and reliable results from a DNA sequencing analyzer and enabling them to create and deploy NGS-based molecular diagnostic tests for cystic fibrosis and a wide-range of other applications.”

Related Links:

Illumina Inc.



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Collection and Transport System
PurSafe Plus®
Capillary Blood Collection Tube
IMPROMINI M3
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)

Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.